![]() |
Name |
8-demethoxy-10-deoxysteffimycin B
|
Molecular Formula | C28H32O11 | |
IUPAC Name* |
4,6,9-trihydroxy-7-(4-hydroxy-3,5-dimethoxy-6-methyloxan-2-yl)oxy-2-methoxy-9-methyl-8,10-dihydro-7H-tetracene-5,12-dione
|
|
SMILES |
COc1cc(O)c2c(c1)C(=O)c1cc3c(c(O)c1C2=O)C(OC1OC(C)C(OC)C(O)C1OC)CC(C)(O)C3
|
|
InChI |
InChI=1S/C28H32O11/c1-11-25(36-4)24(33)26(37-5)27(38-11)39-17-10-28(2,34)9-12-6-14-20(22(31)18(12)17)23(32)19-15(21(14)30)7-13(35-3)8-16(19)29/h6-8,11,17,24-27,29,31,33-34H,9-10H2,1-5H3
|
|
InChIKey |
RPBBLWPRKUUHJZ-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 544.55 | ALogp: | 1.8 |
HBD: | 4 | HBA: | 11 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 161.2 | Aromatic Rings: | 5 |
Heavy Atoms: | 39 | QED Weighted: | 0.373 |
Caco-2 Permeability: | -6.131 | MDCK Permeability: | 0.00000795 |
Pgp-inhibitor: | 0.008 | Pgp-substrate: | 0.989 |
Human Intestinal Absorption (HIA): | 0.841 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.034 |
Blood-Brain-Barrier Penetration (BBB): | 0.005 | Plasma Protein Binding (PPB): | 90.10% |
Volume Distribution (VD): | 0.715 | Fu: | 18.33% |
CYP1A2-inhibitor: | 0.12 | CYP1A2-substrate: | 0.946 |
CYP2C19-inhibitor: | 0.008 | CYP2C19-substrate: | 0.098 |
CYP2C9-inhibitor: | 0.018 | CYP2C9-substrate: | 0.153 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.162 |
CYP3A4-inhibitor: | 0.096 | CYP3A4-substrate: | 0.124 |
Clearance (CL): | 5.026 | Half-life (T1/2): | 0.209 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.384 |
Drug-inuced Liver Injury (DILI): | 0.956 | AMES Toxicity: | 0.545 |
Rat Oral Acute Toxicity: | 0.061 | Maximum Recommended Daily Dose: | 0.247 |
Skin Sensitization: | 0.707 | Carcinogencity: | 0.081 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.04 |
Respiratory Toxicity: | 0.349 |